Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005664809
Thu, 30.04.2026
Evotec SE
Grants support discovery and development of novel drug candidates and evaluation and prioritization of advanced drug regimens for clinical testing
New funding from the Gates Foundation extends Evotec’s commitment to create more effective tuberculosis treatment regimens
Hamburg, Germany, April 30, 2026 – Evotec SE (NASDAQ: EVO; [ … ]
Wed, 29.04.2026
Evotec SE
Evotec Announces New Nomination to Board of Directors
Nomination of Dr. Wolfgang Hofmann as independent Supervisory Board member to further strengthen oversight and governance capabilities
Conclusion of cooperation agreement with MAK Capital following constructive discussions, reflecting Evotec’s commitment to open shareholder dialogue
Annual Ge [ … ]
Fri, 24.04.2026
Evotec SE
Paul Hitchin to step down as of April 30, 2026
Claire Hinshelwood appointed to CFO role as of May 1, 2026
Hamburg, Germany, April 24, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that Chief Financial Officer (CFO) Paul Hitchin will step down on April 30, 2026, for personal reasons unrelated to [ … ]
Wed, 08.04.2026
Evotec SE
Evotec Announces Fourth Quarter and Full-Year 2025 Results: Foundation for Profitable Growth
2025 financial performance at high end of guidance: Q4 and FY group revenues of €253.3 m and €788.4 m, respectively (Q4: €266.7 m, FY: €810.4 m at CER); adj. group EBITDA of €58.0 m and €41.1 m, respectively (Q4: €64.8 m, FY: €52.3 m at CER)
Robust exec [ … ]
Tue, 07.04.2026
Evotec SE
Evotec Nominates Dieter Weinand as Supervisory Board Chairman
Strengthens Supervisory Board leadership to support Evotec’s transformation, with a focus on commercial execution, strategic partnerships and profitability
Industry veteran brings more than 30 years of global pharmaceutical industry leadership experience across senior management, comm [ … ]
Wed, 01.04.2026
Evotec SE
Hamburg, Germany, April 1, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the fourth quarter and full-year 2025 and provide a business update on Wednesday, April 8, 2026. The conference call will be held in English.
Webcast details
Date: Wednesday, April [ … ]
Thu, 19.03.2026
Evotec SE
Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancer
Transformative moment in strategic protein degradation collaboration with Bristol Myers Squibb (BMS) aiming to establish new treatment paradigm in advanced clear [ … ]
Tue, 10.03.2026
Evotec SE
Evotec Announces ‘Horizon’ – Next Inflection in Its Strategic Transformation to Accelerate Growth and Promote Agility
Horizon advances multi-stage transformation initiated with Priority Reset in 2024 and establishes new operating model across three pillars: operations, science and commercial execution
Operations: Global footprint further str [ … ]
Thu, 08.01.2026
Evotec SE
Just – Evotec Biologics will optimize monoclonal antibodies (“mAbs”) and other biologic modalities
Investment enables ten new J.MD™ projects encompassing molecular optimization including, but not limited to: improved titer, pharmacokinetics, immunogenicity, and stability, over the next three years
Hamburg, Germany, January 08, [ … ]
Thu, 01.01.2026
Evotec SE
Evotec appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations
Creation of new Executive Vice President role integrating Global Communications and Investor Relations to strengthen strategic messaging and stakeholder alignment
Hamburg, Germany, January 1, 2026:
Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) toda [ … ]
